RxDoctor Payments Data

Mark Cimini

Optometrist · Coral Gables, FLNPI 1740889385

Payments from drug & device makers

$3,436in general payments, 2019–2025

Across 103 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Aerie Pharmaceuticals, Inc.$404
  • Mallinckrodt Hospital Products Inc.$397
  • Alcon$304
  • Biotissue Holdings Inc.$273
  • Oyster Point Pharma, Inc.$177
  • plus $780 from 9 others

What the payments were for

  • Food & beverage$3,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,436 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$1,749
Medicare patients
15
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost590$169,769
RocklatanNetarsudil Mesylat/Latanoprost147$56,186
CombiganBrimonidine Tartrate/Timolol104$40,069
RestasisCyclosporine46$38,291
RhopressaNetarsudil Mesylate89$33,133
Alphagan PBrimonidine Tartrate48$17,043
Cyclosporine221$11,272
SimbrinzaBrinzolamide/Brimonidine Tart49$11,240
VyzultaLatanoprostene Bunod32$8,874
CequaCyclosporine14$8,657
Latanoprost1,845$8,403
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol199$7,575
Brimonidine Tartrate399$6,704
Prednisolone Acetate257$5,987
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat500$4,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,101$265,171788 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$404$89,319236 claims
AlconSimbrinza$304$11,24049 claims
Bausch & Lomb Americas Inc.Vyzulta$171$8,87432 claims
Sun Pharmaceutical Industries Inc.Cequa$21$8,65714 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$24$2,78027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →